Back to All Combinations

POLE/POLD1 Ultramutated

Good Prognosis
1.00% Prevalence Level 2B Immunotherapy Biomarkers
Actionable Target
FDA-approved targeted therapies or strong clinical trial evidence available
Genes Involved
POLE POLD1
Treatment Implications

Ultramutated (>100 mut/Mb). Exceptional immunotherapy responders.

Recommended Treatments
Pembrolizumab
Nivolumab
Treatments to Avoid

No specific contraindications noted

Study References

TCGA, Case series

Key Statistics
1.00%
Prevalence in CRC
Yes
Targetable
Clinical Notes
Screen for germline POLE/POLD1 (PPAP syndrome).
Information

Category: Immunotherapy Biomarkers

Evidence Level: Level 2B

Last Updated: Dec 7, 2025

Related Combinations
Medical Disclaimer: This information is for educational purposes only and should not replace professional medical advice. Always consult with your oncologist for personalized treatment decisions based on your specific situation.